The differentiation of dendritic cells (DCs) in vitro is not yet under full control and although PPAR-γ stimulation may interfere with DC differentiation from cord blood progenitors, the expression of PPAR-γ by different precursors and the effect of PPAR-γ stimulation on DC differentiation are poorly known. To address these issues, CD14+ monocytes, CD34+ progenitors and CD133+ progenitors were isolated from adult healthy donors and cultured with cytokines; rosiglitazone (1 µmol/l) was used to stimulate PPAR-γ. All precursors generated large, HLA-DR+ DCs, a proportion of which, highest when starting from CD133+ precursors expressed the Langerhans cell marker CD207/langerin; many cells expressed the connective tissue DC marker CD209/DC-SIGN, even together with CD207, and some cells contained Birbeck granules.
Introduction
Dendritic cells, the professional antigen presenting cells of the immune system, deserve attention because they can direct immune response to pathogenic organisms [1] and tumors [2] towards reaction anergy or active tolerance [3, 4] and play crucial roles in allergy, autoimmunity and transplant rejection [5] ; they are also involved in HIV infection by hosting the virus and transferring it to lymphocytes [6] . To play their roles since primary response, dendritic cells express the major histocompatibility complex class I (MHC-I) and class II antigens (MHC-II) and a combination of costimulatory (CD80, CD86) and adhesion molecules (CD54) [7] .
Dendritic cells originate from bone marrow hematopoietic stem cells and two main subsets have been identified: myeloid and plasmacytoid dendritric cells [7, 3, 8] . Only the former (abbreviated as DCs) will be dealt with here. Among them one recognizes interstitial DCs of connective tissue proper -which express CD1c, DC-SIGN/CD209, DEC205 and, sometimes, also CD1a -and Langerhans cells (LCs) in stratified squamous epithelia of the skin and mucosae. The latter express Ecadherin, CD1a and CD207 and contain a specific inclusion, Birbeck granules, visible by electron microscopy [9] . Upon antigen capture mDCs mature and come to express CD83 and the co-stimulatory molecules CD54, CD80 and CD86 together with increased amounts of MHC-II.
In vitro, DCs can differentiate from circulating CD14+ and CD14-monocytes [10] [11] [12] , from CD34+ progenitors and from CD133+ precursors; the last cells have been used only in a few studies [13] [14] [15] . Attempts to drive the differentiation towards specific subtypes of DCs, in particular towards LCs, have given inconsistent results, the best ones have been obtained starting from CD14-cells of adult peripheral blood [11] and from CD34+ [16] or CD133+ precursors isolated from cord blood [15] . The lipid signal molecules receptor PPAR-γ has been included among the pathways possibly involved in immune system regulation, since it is expressed in humans by at least some hematopoietic cells [17] and some cells of the immune system [18] [19] [20] , either spontaneously or upon culture with rosiglitazone, an agonist of this receptor [21, 22] .
Differentiation of DCs in the presence of PPAR-γ ligands has an inhibiting effect on immunogenicity, possibly through inhibition of several signal pathways [23, 24] and of co-stimulatory molecules expression [18, 21, [25] [26] [27] . During differentiation of DCs from CD133+ haematopoietic precursors of the cord blood, rosiglitazone favoured the full differentiation of lymphocyte-stimulating LCs expressing CD207/langerin and containing Birbeck granules, but at the expense of the number of generated cells [15] .
Because of their roles, dendritic cells are emerging as attractive targets and mediators of immune therapies designed to promote or attenuate the immune responses [28] , however the possibility of influencing their behaviour is still limited, largely due to incomplete knowledge of their differentiation and its regulation, including the differentiation potential of different circulating precursors of adults into DCs and their subtypes and the influence of PPAR-γ on this process.
To address these issues, experiments were started with the selection of circulating precursors according to the expression of either CD14 or CD34 or CD133. The cells were cultivated with cytokines to generate immature DCs and then further cultivated with a different cytokine mixture to induce maturation, and the effect of rosiglitazone was tested by its addition throughout culture. The generated cells were analyzed for immunophenotype, morphology, and the ability to stimulate mixed lymphocyte reaction (MLR).
Materials and Methods

Isolation and culture of circulating precursor cells
All cells were isolated from buffy coats obtained from healthy donors in the respect of the Italian law and upon approval of the local ethical committee (authorization n° 0011762/2010). Each donor was used for one experiment.
CD14+ precursors
Human buffy coats were stored at +4 °C for 24 h before use and then subjected to density gradient centrifugation on Ficoll (Lymphoprep, Euroclone, Pero, Italy) followed by immunomagnetic separation of CD14+ cells, following a previously published protocol [12, 29] . In detail, the buffy coat was suspended in 2,5% dextran (Amersham Pharmacia Biotech, Sweden) in 0.9% NaCl and stabilized at 37 °C for 30 min. Upon dilution with phosphate buffered saline 0.1 mol/litre, pH 7.4 (PBS), the suspension was stratified over Ficoll and centrifuged for 15 min at 800 x g. Upon washing in PBS with 1%, heat inactivated, foetal bovine serum (FBS; Sigma-Aldrich, St Louis, Mo, USA), colloidal superparamagnetic microbeads conjugated with mouse anti-human CD14 monoclonal antibody (Microbeads UltraPure, human, Miltenyi Biotec, Bergisch
Gladbach, Germany) were added to the cell suspension (20 µl beads per 10 7 total cells) and let incubate at 4 °C for 15 min.
After washing with PBS the cell suspension was loaded onto a MACS column (Miltenyi Biotec) which was placed in a magnetic field MACS Separator (Miltenyi Biotec). After elution of unlabelled cells, the column was extracted from the magnet and CD14+ cells were recovered with PBS. The cells were seeded at mean concentration of 1x10 6 cells/ml in RPMI 1640 with 10% FBS, 100 U/ml penicillin and 0.1 ng/ml streptomycin (all from Sigma-Aldrich), GM-CSF (10 ng/ml), IL-4 (10 ng/ml), TNF-α (10 ng/ml) and TGF-β (10 ng/ml) for 7 days; final maturation was induced with the same cytokines plus IL-1β (10 ng/ml), IL-6 (1000 U/ml) and TGF-β (20 ng/ml) for additional 24 h. All cytokines were purchased from PeproTech. For TGF-β the isoform 3 was used:
the three isoforms of TGF-β signal through the same receptor and elicit similar biological responses [30] .
CD34+ precursors
To obtain human CD34+ cells, freshly recovered buffy coats were used. The mononuclear cells were isolated by Ficoll density gradient centrifugation as indicated above and up to 10 8 cells were resuspended in a final volume of 300 µl PBS and labelled with superparamagnetic microbeads conjugated with mouse anti-human CD34 monoclonal antibodies for 30 min at 4° C, according to the producer instructions (Microbeads UltraPure, human, Miltenyi Biotec). The cell suspension was loaded onto a column and subjected to magnetic field separation as indicated above. After removing the column from the magnetic field, the retained CD34+ cells were eluted and counted.
Purified CD34+ cells (500,000 cells/ml) were seeded in RPMI 1640 with FBS, penicillin and streptomycin as above indicated and cultivated for 7 days with SCF (20 ng/ml), TPO (10 ng/ml), Flt3-L (25 ng/ml), GM-CSF (10 ng/ml), IL-4 (10 ng/ml), TGF-β (10 ng/ml; all cytokines from Peprotech). The culture was further continued for 7 more days with GM-CSF, IL-4, TNF-α and TGF-β, at the same concentrations indicated above for CD14+ cells. For last additional four days, i.e.
from day 14 to day 18 of culture, IL-1β (10 ng/ml) and IL-6 (1000 U/ml; both from Peprotech) were also added and TGF-β concentration was raised to 20 ng/ml, while GM-CSF, IL-4 and TNF-α were maintained at the same concentration indicated above.
CD133+ precursors
To obtain human CD133+ cells, freshly recovered buffy coats were used. The mononuclear cells were isolated by Ficoll density gradient centrifugation as described above, then resuspended in a final volume of 200 µl PBS for up to 5x10 7 cells and subjected to two-step immuno-magnetic purification with Diamond human CD133 isolation kit (Miltenyi Biotec; the kit includes all primary antibodies and two types of microbead-linked secondary antibodies) following the indications of the producer. In a first step the cells were incubated with a cocktail of biotin-conjugated mouse monoclonal antibodies against human CD2, CD3, CD11b, CD14, CD15, CD16, CD19, CD56, CD61 and CD253a, for 10 min at 4 °C, washed in PBS and resuspended in 400 µl PBS. Anti-biotin microbeads were added for 15 min at 4 °C, then the cell suspension was loaded onto a column and subjected to magnetic field separation. In a second step the unlabelled, effluent cells were washed and resuspended in 200 µl PBS (up to 5x10 7 per sample), adding 50 µl of micro beads conjugated with monoclonal CD133 antibodies for 30 min at 4 °C. Upon subsequent magnetic separation, the CD133+ cells were eluted and placed in cult0ure with the same cytokines and for the same times indicated for CD34+ cell culture.
Rosiglitazone challenge
The cells isolated from each donor -whichever precursor had been isolated -were split in two and rosiglitazone other half cells were cultured without rosiglitazone as control. The drug was obtained from the producer as a powder and was dissolved in dimethyl sulfoxide at a concentration of 100 mmol/l for storage. It was then diluted in 0.1% bovine serum albumin (BSA) in PBS down to 100 µmol/l before adding to the culture medium at the indicated final concentration.
Generated cells were analysed at the end of culture. 
Immunofluorescence
Flow cytometry
In all analyses, the indicated amounts of the following monoclonal antibody solutions were added to 100 µl of cell using the cell permeabilization kit of Nordic-Mubio (Susteren, Netherlands) according to the directions of the manufacturer.
Flow cytometry was performed by collecting more than 10,000 events on a FACSCanto II (BD Biosciences ) and data were analysed with Infinicyt 1.7 (Citognos, Salamanca, Spain).
Electron microscopy
Cell pellets were fixed in 2% formaldehyde and 2.5% glutaraldehyde in 0. Software, Muenster, Germany).
Mixed lymphocyte reaction
Allogeneic lymphocytes were recovered from buffy coats -obtained from healthy donors and stored at +4 °C for 24 h 
Gene expression
The expression of PPAR-γ was evaluated by quantitative qRT-PCR using Cells-to-CT 1-Step TaqMan Kit (Thermo ) were isolated. The cells harvested at the end of culture were less than those seeded: ~75% of CD14+ precursors, ~60% of CD34+ and CD133+ precursors. Cell morphology and vitality were not affected by the addition of rosiglitazone to the culture medium.
Cells differentiated from CD14+ monocytes
Most cells generated from CD14+ precursors showed a dendritic morphology after 7 days. The latter cells were homogeneous for both forward and side scatter and virtually all (98%) were HLA-DR+. Fifty-eight per cent cells expressed CD1a.
The percentage of HLA-DR+ DCs generated from CD14+ monocytes which expressed CD207 ranged between 4 and 6% and did not vary appreciably when cells were labelled after permeabilization. The results were not influenced by the addition of rosiglitazone. Immunohistochemistry confirmed the very low expression of CD207 by differentiated cells while ~95% expressed CD209 (not shown).
At electron microscopy, some DCs differentiated from CD14+ monocytes contained electron dense lysosomes and thin curved cisternae, presumably cup-shaped, with electron dense content ( Figure 1A , B, G).
The expression of PPAR-by CD14+ monocytes was negligible (0.57±0.360 copies/cell, N=3).
Cells differentiated from CD34+ precursors
The cells obtained from CD34+ precursors could be divided into two populations, one CD33+ CD45+ and the other CD33-CD45+. This latter population was excluded from analysis, because the lack of CD33 prevented to identify those cells as Immunohistochemistry confirmed the co-expression of CD207 and CD209, and showed that of CD54 (Figure 3 ).
At electron microscopy, the harvested cells included large and medium size DCs and small, roundish cells. The largest cells were highly dendritic and rich in mitochondria, rough and smooth endoplasmic reticulum, Golgi apparatus and lysosomes. The medium size cells had shorter and poorly branched dendrites and less abundant organelles than large cells.
The smallest cells had a smooth surface and were poor in organelles, except for many free ribosomes ( Figure 1C, D) .
Curved cisternae were present in DCs and occasional straight, rudimentary Birbeck granules ( Figure 1H ) were recognized in large DCs. The expression of PPAR-by CD34+ precursors was negligible (0.01±0.004 copies/cell, N=3).
Cells differentiated from CD133+ precursors
Also the DCs obtained from CD133+ precursors could be divided into a CD33+ CD45+ and a CD33-CD45+ population and only the first one (about 60-70% of harvested cells) was subjected to further analysis. They were all HLA-DR+; 53-94% cells were LC-like, both with and without rosiglitazone, as appreciated by scatter parameters and the expression of 
Mixed lymphocyte reaction
The proliferation of CD4+ lymphocytes after 5 d co-culture with DCs derived from CD133+ precursors was significantly higher than that of lymphocytes alone. The use of CFSE dilution as a measure of proliferation allowed to recognize that the proliferative response of CD8+ lymphocytes to DCs was much lower than that of CD4+ lymphocytes; both appeared decreased when DCs had been differentiated in the presence of rosiglitazone, the difference being significant for CD4+ lymphocytes ( Figure 4 ). 
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Discussion
The results of this study have shown that DCs can be generated from different precursors obtained from adult human blood and that they include cells with features of a specific DC type, i.e. LCs; that the percentage of this last cell type and more in general the phenotype and functional ability of the generated DCs depend on the precursor; that the phenotype of generated This study moreover confirmed previous results on precursors from cord blood [15] , that the cells that can be harvested upon culture in conditions useful to generate DCs are less than the seeded cells, i.e. there is only limited proliferation, except in the first days of culture.
At variance with previous results of this laboratory on CD133+ cord blood cells [15] , culture of CD133+ precursors from adult blood with the PPAR-γ agonist rosiglitazone did not restrict the generated cells to a small number of cells with features of LCs, although such cells were indeed increased in those conditions as compared with cultures without the drug.
It cannot be excluded that this depends on technical reasons because in the meantime from previous research the cytokines and the isolation kit have been bought new and were from different lots and in some cases different producers than in the study on cord blood cells, and also rosiglitazone had to be obtained new and from a different producer. However, it is reasonable to conceive that the differentiation potential and response to PPAR-γ agonists differ between foetus and adult.
Large DCs with mature features at electron microscopy, i.e. rich in organelles and especially lysosomes, contained inclusions resembling Birbeck granules. Moreover, they contained flat, curved cisternae that were delimited by parallel membranes and had a central density over most of there extension; the images resemble those of the inclusions elicited by anti-CD1a treatment of human epidermal LCs [32] .
At variance with what is usually observed in vivo, the cells with LC features, namely a typical scatter pattern at flow cytometry and the expression of CD207 and CD1a at immunophenotypical analysis, also expressed CD209 which instead is typical of connective tissue, non-Langerhans DCs [33] . This was true with either CD133+ or CD34+ cells as starting expressing cells, as expected [34] . The results upon rosiglitazone indicate that this drug has significant effects on the expression of CD207 only in cells generated from CD133+ precursors, where it stimulates the expression of CD207, both in the whole cell and at the cell surface. It is conceivable that this depends on the expression of PPAR-γ being appreciable in CD133+ cells and negligeable in the other cellular precursors considered in this study; the results also suggest that the observed effects of PPAR-γ stimulation on the differentiation of DCs depend on an action on very early stages of the process. The very small number of cells with LC-like features starting from CD14+ precursors is in substantial agreement with literature reports [35, 36] . A previous study by another laboratory had shown that rosiglitazone can induce the expression in culture of PPAR-γ when starting from CD14+ cells [28] ; in the present study, however, such a treatment on cultures of CD14+ monocytes did not have an effect on immunophenotype.
The results upon rosiglitazone may have counterparts in vitro, because both connective tissue cells and keratinocytes can secrete molecules acting as PPAR-γ stimulants and so regulate the final differentiation and function of DCs [37] [38] [39] .
The effect of rosiglitazone on the differentiation of DCs from CD133+ precursors was a stimulation of the expression of LC markers and a partial inhibition of the lymphocyte proliferation stimulating ability of the generated cells. The possibility that this depended on piggyback transfer of rosiglitazone to lymphocytes by DCs is highly improbable because DCs were extensively washed before transferring into co-culture wells for MLR. Also, it had been demonstrated by Nencioni et al. [18] and Appel et al. [23] that DCs generated from CD14+ precursors in the presence of PPAR-γ agonists had impaired T cell stimulating activity. It may be correlated with this effect of PPAR-γ stimulation the fact that in a mouse model of atopic dermatitis PPAR-γ agonists led to decreased severity of the disease and to selective inhibition of the maturation in vitro of DCs derived from untreated animals [40] .
The use of CFSE for evaluating the proliferation of the lymphocytes in MLR allowed to recognize a different effect of DCs generated in vitro from CD133+ precursors on CD4+ and CD8+ lymphocytes: these cells stimulated CD4+
lymphocytes, but were very poorly effective on CD8+ lymphocytes. Correspondingly, the negative influence of rosiglitazone on the lymphocyte stimulating capacity of DCs generated from CD133+ precursors was higher towards CD4+ than CD8+ lymphocytes. The varying capacity of DCs to stimulate different lymphocyte subsets and the varying influence of PPAR-γ agonists on those subset should be taken into account both for the interpretation of results on a mixed lymphocyte population (as most often occurs) and for the planning of strategies for the clinical use of in vitro generated and manipulated DCs and of drugs acting on those cells in vivo. contributed to only one experiment. On account of the Italian law on privacy and personal data protection no information was available on the donors (not even sex or age), the only information being that they were healthy subjects acceptable as blood donors for transfusion. This drawback is intrinsic to studies with human cells and could not be avoided in this research either.
The findings of this research may be relevant to the question whether in order to induce, enhance or alternatively lower an immune response it would be better to differentiate DCs from haematopoietic precursors in vitro and inject them into a patient upon appropriate treatment, or find ways to influence the DCs of a patient in vivo, as also proposed in the clinics [2] . The latter strategy would obviate the imperfect control of the differentiation of DCs in vitro and the risk of raising cells prone to induce responses inappropriate to the single case which they would be supposed to cure.
